Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
33,098,025
-
Share change
-
-525,702
-
Total reported value
-
$164,832,029
-
Price per share
-
$4.98
-
Number of holders
-
46
-
Value change
-
-$2,952,586
-
Number of buys
-
24
-
Number of sells
-
12
Institutional Holders of THESEUS PHARMACEUTICALS INC - COM (THRX) as of Q4 2022
As of 31 Dec 2022,
THESEUS PHARMACEUTICALS INC - COM (THRX) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,098,025 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Foresite Capital Management V, LLC, FMR LLC, Frazier Life Sciences Management, L.P., PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., Lynx1 Capital Management LP, Omega Fund Management, LLC, VANGUARD GROUP INC, and Nextech Invest Ltd..
This page lists
46
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.